What is the long-term trend for Exelixis's cash, cash equivalents, and marketable securities?

Over 5 years (2020 to 2025), Exelixis's cash, cash equivalents, and marketable securities has grown at a 3.9% compound annual growth rate (CAGR), from $56.3M to $68.3M.

Exelixis EXEL Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Ionis PharmaceuticalsIONS

$1.03B+28.1%

BridgeBio PharmaBBIO

——

Neurocrine BiosciencesNBIX

——

AmgenAMGN

——

ModernaMRNA

——

Other financials

Income statement

See full

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

See full

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

See full

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation

See full

Market cap$13.05B+10.1%

Enterprise value$12.99B+9.5%

P/E15.7×-2.8×

P/S5.5×+0.3×

Profitability

See full

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

See full

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exelixis's cash, cash equivalents, and marketable securities?: Exelixis (EXEL) reported cash, cash equivalents, and marketable securities of $488.33M in Q1 2026.
How has Exelixis's cash, cash equivalents, and marketable securities changed year-over-year?: Exelixis's cash, cash equivalents, and marketable securities increased by 5.1% year-over-year, from $464.66M to $488.33M.
What is the long-term trend for Exelixis's cash, cash equivalents, and marketable securities?: Over 5 years (2020 to 2025), Exelixis's cash, cash equivalents, and marketable securities has grown at a 3.9% compound annual growth rate (CAGR), from $56.3M to $68.3M.